TY - JOUR
T1 - Temporal trends and outcomes of patients undergoing percutaneous coronary interventions for cardiogenic shock in the setting of acute myocardial infarction
T2 - A report from the cathpci registry
AU - Wayangankar, Siddharth A.
AU - Bangalore, Sripal
AU - McCoy, Lisa A.
AU - Jneid, Hani
AU - Latif, Faisal
AU - Karrowni, Wassef
AU - Charitakis, Konstantinos
AU - Feldman, Dmitriy N.
AU - Dakik, Habib A.
AU - Mauri, Laura
AU - Peterson, Eric D.
AU - Messenger, John
AU - Roe, Mathew
AU - Mukherjee, Debabrata
AU - Klein, Andrew
N1 - Funding Information:
This research was supported by the American College of Cardiology Foundation’s National Cardiovascular Data Registry (NCDR). The views expressed in this manuscript represent those of the author(s), and do not necessarily represent the official views of the NCDR or its associated professional societies identified at www.ncdr.com .
Funding Information:
Dr. Bangalore has a financial relationship with Pfizer. Dr. Feldman is a consultant/member of the Speakers Bureau for Eli Lilly, Daiichi-Sankyo, Abbott Vascular, Pfizer, and Bristol-Myers Squibb. Dr. Mauri's institution has received grants from Abbott (research grant), Boston Scientific, Cordis, Medtronic, Eli Lilly, Daiichi-Sankyo, Bristol Myers Squibb, and Sanofi; and she is a consultant for Cordis/Medtronic. Dr. Peterson has a financial relationship and has received research grants from Eli Lilly and Janssen Pharmaceutical Products; and is a consultant for Boehringer Ingelheim, Janssen Pharmaceutical Products, Merck & Co., and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2016 American College of Cardiology Foundation. Published by Elsevier.
PY - 2016/2/22
Y1 - 2016/2/22
N2 - Objectives The purpose of this study was to examine the temporal trends in demographics, clinical characteristics, management strategies, and in-hospital outcomes in patients with acute myocardial infarction complicated by cardiogenic shock (CS-AMI) who underwent percutaneous coronary intervention (PCI) from the Cath-PCI Registry (2005 to 2013). Background The authors examined contemporary use and outcomes of PCI in patients with CS-AMI. Methods The authors used the Cath-PCI Registry to evaluate 56,497 patients (January 2005 to December 2013) undergoing PCI for CS-AMI. Temporal trends in clinical variables and outcomes were assessed. Results Compared with cases performed from 2005 to 2006, CS-AMI patients receiving PCI from 2011 to 2013 were more likely to have diabetes, hypertension, dyslipidemia, previous PCI, dialysis, but less likely to have chronic lung disease, peripheral vascular disease, or heart failure within 2 weeks (p < 0.01). Between 2005 and 2006 to 2011 and 2013, intra-aortic balloon pump use decreased (49.5% to 44.9%; p < 0.01), drug-eluting stent use declined (65% to 46%; p < 0.01), and the use of bivalirudin increased (12.6% to 45.6%). Adjusted in-hospital mortality; increased (27.6% in 2005 to 2006 vs. 30.6% in 2011 to 2013, adjusted odds ratio: 1.09, 95% confidence interval: 1.005 to.173; p = 0.04) for patients who were managed with an early invasive strategy (<24 h from symptoms). Conclusions Our study shows that despite the evolution of medical technology and use of contemporary therapeutic measures, in-hospital mortality in CS-AMI patients who are managed invasively continues to rise. Additional research and targeted efforts are indicated to improve outcomes in this high-risk cohort.
AB - Objectives The purpose of this study was to examine the temporal trends in demographics, clinical characteristics, management strategies, and in-hospital outcomes in patients with acute myocardial infarction complicated by cardiogenic shock (CS-AMI) who underwent percutaneous coronary intervention (PCI) from the Cath-PCI Registry (2005 to 2013). Background The authors examined contemporary use and outcomes of PCI in patients with CS-AMI. Methods The authors used the Cath-PCI Registry to evaluate 56,497 patients (January 2005 to December 2013) undergoing PCI for CS-AMI. Temporal trends in clinical variables and outcomes were assessed. Results Compared with cases performed from 2005 to 2006, CS-AMI patients receiving PCI from 2011 to 2013 were more likely to have diabetes, hypertension, dyslipidemia, previous PCI, dialysis, but less likely to have chronic lung disease, peripheral vascular disease, or heart failure within 2 weeks (p < 0.01). Between 2005 and 2006 to 2011 and 2013, intra-aortic balloon pump use decreased (49.5% to 44.9%; p < 0.01), drug-eluting stent use declined (65% to 46%; p < 0.01), and the use of bivalirudin increased (12.6% to 45.6%). Adjusted in-hospital mortality; increased (27.6% in 2005 to 2006 vs. 30.6% in 2011 to 2013, adjusted odds ratio: 1.09, 95% confidence interval: 1.005 to.173; p = 0.04) for patients who were managed with an early invasive strategy (<24 h from symptoms). Conclusions Our study shows that despite the evolution of medical technology and use of contemporary therapeutic measures, in-hospital mortality in CS-AMI patients who are managed invasively continues to rise. Additional research and targeted efforts are indicated to improve outcomes in this high-risk cohort.
KW - acute coronary syndrome(s)
KW - acute myocardial infarction
KW - cardiogenic shock
KW - percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=84958948368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958948368&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2015.10.039
DO - 10.1016/j.jcin.2015.10.039
M3 - Article
C2 - 26803418
AN - SCOPUS:84958948368
SN - 1936-8798
VL - 9
SP - 341
EP - 351
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 4
ER -